NASDAQ:TCRX TScan Therapeutics Q2 2026 Earnings Results & Report $0.19 +0.00 (+0.22%) Closing price 04:00 PM EasternExtended Trading$0.18 0.00 (-0.32%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. TScan Therapeutics beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$0.23 versus the -$0.2534 consensus estimate, while revenue of $1.05 million fell short of the $1.88 million estimate by $824.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 12, 2026TimeBefore Market OpensConference Call7:00 AM ET TScan Therapeutics EPS ResultsActual EPS-$0.23Consensus EPS -$0.2534Beat/MissBeat by +$0.0234One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersTScan Therapeutics Revenue ResultsActual Revenue$1.05 millionExpected Revenue$1.88 millionBeat/MissMissed by -$824.00 thousandYoY Revenue GrowthN/AUpcoming EarningsTScan Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) TScan Therapeutics Q2 2026 Earnings FAQ Did TScan Therapeutics beat earnings estimates for Q2 2026? TScan Therapeutics (NASDAQ:TCRX) reported earnings of -$0.23 per share for Q2 2026, beating the consensus estimate of -$0.2534. The report was announced on Wednesday, August 12, 2026. What was TScan Therapeutics' revenue for Q2 2026? TScan Therapeutics reported revenue of $1.05 million for Q2 2026, against a consensus estimate of $1.88 million. When is TScan Therapeutics' next earnings date? TScan Therapeutics' next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for TScan Therapeutics on the company's earnings history page. TScan Therapeutics Earnings HeadlinesTScan Therapeutics (TCRX) Expected to Post Quarterly Earnings on WednesdayNovember 10 at 2:43 AM | americanbankingnews.comTScan Therapeutics Announces Board and Governance ChangesOctober 16, 2026 | tipranks.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.November 11 at 1:00 AM | Porter & Company (Ad)TScan Therapeutics consensus price target decreased by 55.56% to $2.72September 16, 2026 | msn.comWedbush downgrades TScan Therapeutics (TCRX) to neutral from outperformSeptember 3, 2026 | msn.comTScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%September 2, 2026 | rttnews.comSee More TScan Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TScan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your email. Email Address About TScan TherapeuticsTScan Therapeutics (NASDAQ:TCRX) is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells. The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant. TScan is also advancing additional TCR-T candidates against targets associated with solid tumors through its discovery and development platforms. Founded in 2018 and headquartered in Waltham, Massachusetts, TScan conducts research and clinical development primarily in the United States. Its therapies remain investigational and are not approved for commercial use. The company has been led by Chief Executive Officer David Southwell.View TScan Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
